Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Visceral Leishmaniasis Market

ID: MRFR/Pharma/37783-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Visceral Leishmaniasis Market Research Report: Size, Share, Trend Analysis By Diagnosis Method (Serological Tests, Molecular Tests, Microscopy, Culture Methods), By Treatment Type (Antimonials, Amphotericin B, Miltefosine, Paromomycin), By End Users (Hospitals, Diagnostic Laboratories, Research Institutions) and  By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)  - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Visceral Leishmaniasis Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Diagnosis Method (USD Billion)
  49.     4.1.1 Serological Tests
  50.     4.1.2 Molecular Tests
  51.     4.1.3 Microscopy
  52.     4.1.4 Culture Methods
  53.   4.2 Healthcare, BY Treatment Type (USD Billion)
  54.     4.2.1 Antimonials
  55.     4.2.2 Amphotericin B
  56.     4.2.3 Miltefosine
  57.     4.2.4 Paromomycin
  58.   4.3 Healthcare, BY End User (USD Billion)
  59.     4.3.1 Hospitals
  60.     4.3.2 Diagnostic Laboratories
  61.     4.3.3 Research Institutions
  62.   4.4 Healthcare, BY Region (USD Billion)
  63.     4.4.1 North America
  64.       4.4.1.1 US
  65.       4.4.1.2 Canada
  66.     4.4.2 Europe
  67.       4.4.2.1 Germany
  68.       4.4.2.2 UK
  69.       4.4.2.3 France
  70.       4.4.2.4 Russia
  71.       4.4.2.5 Italy
  72.       4.4.2.6 Spain
  73.       4.4.2.7 Rest of Europe
  74.     4.4.3 APAC
  75.       4.4.3.1 China
  76.       4.4.3.2 India
  77.       4.4.3.3 Japan
  78.       4.4.3.4 South Korea
  79.       4.4.3.5 Malaysia
  80.       4.4.3.6 Thailand
  81.       4.4.3.7 Indonesia
  82.       4.4.3.8 Rest of APAC
  83.     4.4.4 South America
  84.       4.4.4.1 Brazil
  85.       4.4.4.2 Mexico
  86.       4.4.4.3 Argentina
  87.       4.4.4.4 Rest of South America
  88.     4.4.5 MEA
  89.       4.4.5.1 GCC Countries
  90.       4.4.5.2 South Africa
  91.       4.4.5.3 Rest of MEA
  92. 5 SECTION V: COMPETITIVE ANALYSIS
  93.   5.1 Competitive Landscape
  94.     5.1.1 Overview
  95.     5.1.2 Competitive Analysis
  96.     5.1.3 Market share Analysis
  97.     5.1.4 Major Growth Strategy in the Healthcare
  98.     5.1.5 Competitive Benchmarking
  99.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  100.     5.1.7 Key developments and growth strategies
  101.       5.1.7.1 New Product Launch/Service Deployment
  102.       5.1.7.2 Merger & Acquisitions
  103.       5.1.7.3 Joint Ventures
  104.     5.1.8 Major Players Financial Matrix
  105.       5.1.8.1 Sales and Operating Income
  106.       5.1.8.2 Major Players R&D Expenditure. 2023
  107.   5.2 Company Profiles
  108.     5.2.1 GSK (GB)
  109.       5.2.1.1 Financial Overview
  110.       5.2.1.2 Products Offered
  111.       5.2.1.3 Key Developments
  112.       5.2.1.4 SWOT Analysis
  113.       5.2.1.5 Key Strategies
  114.     5.2.2 Bristol-Myers Squibb (US)
  115.       5.2.2.1 Financial Overview
  116.       5.2.2.2 Products Offered
  117.       5.2.2.3 Key Developments
  118.       5.2.2.4 SWOT Analysis
  119.       5.2.2.5 Key Strategies
  120.     5.2.3 Sanofi (FR)
  121.       5.2.3.1 Financial Overview
  122.       5.2.3.2 Products Offered
  123.       5.2.3.3 Key Developments
  124.       5.2.3.4 SWOT Analysis
  125.       5.2.3.5 Key Strategies
  126.     5.2.4 Merck & Co. (US)
  127.       5.2.4.1 Financial Overview
  128.       5.2.4.2 Products Offered
  129.       5.2.4.3 Key Developments
  130.       5.2.4.4 SWOT Analysis
  131.       5.2.4.5 Key Strategies
  132.     5.2.5 Novartis (CH)
  133.       5.2.5.1 Financial Overview
  134.       5.2.5.2 Products Offered
  135.       5.2.5.3 Key Developments
  136.       5.2.5.4 SWOT Analysis
  137.       5.2.5.5 Key Strategies
  138.     5.2.6 Pfizer (US)
  139.       5.2.6.1 Financial Overview
  140.       5.2.6.2 Products Offered
  141.       5.2.6.3 Key Developments
  142.       5.2.6.4 SWOT Analysis
  143.       5.2.6.5 Key Strategies
  144.     5.2.7 Bayer (DE)
  145.       5.2.7.1 Financial Overview
  146.       5.2.7.2 Products Offered
  147.       5.2.7.3 Key Developments
  148.       5.2.7.4 SWOT Analysis
  149.       5.2.7.5 Key Strategies
  150.     5.2.8 AbbVie (US)
  151.       5.2.8.1 Financial Overview
  152.       5.2.8.2 Products Offered
  153.       5.2.8.3 Key Developments
  154.       5.2.8.4 SWOT Analysis
  155.       5.2.8.5 Key Strategies
  156.     5.2.9 Amgen (US)
  157.       5.2.9.1 Financial Overview
  158.       5.2.9.2 Products Offered
  159.       5.2.9.3 Key Developments
  160.       5.2.9.4 SWOT Analysis
  161.       5.2.9.5 Key Strategies
  162.   5.3 Appendix
  163.     5.3.1 References
  164.     5.3.2 Related Reports
  165. 6 LIST OF FIGURES
  166.   6.1 MARKET SYNOPSIS
  167.   6.2 NORTH AMERICA MARKET ANALYSIS
  168.   6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
  169.   6.4 US MARKET ANALYSIS BY TREATMENT TYPE
  170.   6.5 US MARKET ANALYSIS BY END USER
  171.   6.6 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD
  172.   6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
  173.   6.8 CANADA MARKET ANALYSIS BY END USER
  174.   6.9 EUROPE MARKET ANALYSIS
  175.   6.10 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
  176.   6.11 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
  177.   6.12 GERMANY MARKET ANALYSIS BY END USER
  178.   6.13 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
  179.   6.14 UK MARKET ANALYSIS BY TREATMENT TYPE
  180.   6.15 UK MARKET ANALYSIS BY END USER
  181.   6.16 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD
  182.   6.17 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
  183.   6.18 FRANCE MARKET ANALYSIS BY END USER
  184.   6.19 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
  185.   6.20 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
  186.   6.21 RUSSIA MARKET ANALYSIS BY END USER
  187.   6.22 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD
  188.   6.23 ITALY MARKET ANALYSIS BY TREATMENT TYPE
  189.   6.24 ITALY MARKET ANALYSIS BY END USER
  190.   6.25 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD
  191.   6.26 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
  192.   6.27 SPAIN MARKET ANALYSIS BY END USER
  193.   6.28 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
  194.   6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
  195.   6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
  196.   6.31 APAC MARKET ANALYSIS
  197.   6.32 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
  198.   6.33 CHINA MARKET ANALYSIS BY TREATMENT TYPE
  199.   6.34 CHINA MARKET ANALYSIS BY END USER
  200.   6.35 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
  201.   6.36 INDIA MARKET ANALYSIS BY TREATMENT TYPE
  202.   6.37 INDIA MARKET ANALYSIS BY END USER
  203.   6.38 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
  204.   6.39 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
  205.   6.40 JAPAN MARKET ANALYSIS BY END USER
  206.   6.41 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
  207.   6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
  208.   6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
  209.   6.44 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
  210.   6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
  211.   6.46 MALAYSIA MARKET ANALYSIS BY END USER
  212.   6.47 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD
  213.   6.48 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
  214.   6.49 THAILAND MARKET ANALYSIS BY END USER
  215.   6.50 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD
  216.   6.51 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
  217.   6.52 INDONESIA MARKET ANALYSIS BY END USER
  218.   6.53 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD
  219.   6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
  220.   6.55 REST OF APAC MARKET ANALYSIS BY END USER
  221.   6.56 SOUTH AMERICA MARKET ANALYSIS
  222.   6.57 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD
  223.   6.58 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
  224.   6.59 BRAZIL MARKET ANALYSIS BY END USER
  225.   6.60 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD
  226.   6.61 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
  227.   6.62 MEXICO MARKET ANALYSIS BY END USER
  228.   6.63 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD
  229.   6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
  230.   6.65 ARGENTINA MARKET ANALYSIS BY END USER
  231.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD
  232.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  233.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
  234.   6.69 MEA MARKET ANALYSIS
  235.   6.70 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD
  236.   6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
  237.   6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
  238.   6.73 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD
  239.   6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
  240.   6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
  241.   6.76 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD
  242.   6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
  243.   6.78 REST OF MEA MARKET ANALYSIS BY END USER
  244.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  245.   6.80 RESEARCH PROCESS OF MRFR
  246.   6.81 DRO ANALYSIS OF HEALTHCARE
  247.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  248.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  249.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  250.   6.85 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
  251.   6.86 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
  252.   6.87 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  253.   6.88 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
  254.   6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
  255.   6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  256.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  257. 7 LIST OF TABLES
  258.   7.1 LIST OF ASSUMPTIONS
  259.     7.1.1
  260.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  261.     7.2.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  262.     7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  263.     7.2.3 BY END USER, 2025-2035 (USD Billion)
  264.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  265.     7.3.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  266.     7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  267.     7.3.3 BY END USER, 2025-2035 (USD Billion)
  268.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  269.     7.4.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  270.     7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  271.     7.4.3 BY END USER, 2025-2035 (USD Billion)
  272.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  273.     7.5.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  274.     7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  275.     7.5.3 BY END USER, 2025-2035 (USD Billion)
  276.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  277.     7.6.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  278.     7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  279.     7.6.3 BY END USER, 2025-2035 (USD Billion)
  280.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  281.     7.7.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  282.     7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  283.     7.7.3 BY END USER, 2025-2035 (USD Billion)
  284.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  285.     7.8.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  286.     7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  287.     7.8.3 BY END USER, 2025-2035 (USD Billion)
  288.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  289.     7.9.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  290.     7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  291.     7.9.3 BY END USER, 2025-2035 (USD Billion)
  292.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  293.     7.10.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  294.     7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  295.     7.10.3 BY END USER, 2025-2035 (USD Billion)
  296.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  297.     7.11.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  298.     7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  299.     7.11.3 BY END USER, 2025-2035 (USD Billion)
  300.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  301.     7.12.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  302.     7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  303.     7.12.3 BY END USER, 2025-2035 (USD Billion)
  304.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  305.     7.13.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  306.     7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  307.     7.13.3 BY END USER, 2025-2035 (USD Billion)
  308.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  309.     7.14.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  310.     7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  311.     7.14.3 BY END USER, 2025-2035 (USD Billion)
  312.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  313.     7.15.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  314.     7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  315.     7.15.3 BY END USER, 2025-2035 (USD Billion)
  316.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  317.     7.16.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  318.     7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  319.     7.16.3 BY END USER, 2025-2035 (USD Billion)
  320.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  321.     7.17.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  322.     7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  323.     7.17.3 BY END USER, 2025-2035 (USD Billion)
  324.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  325.     7.18.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  326.     7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  327.     7.18.3 BY END USER, 2025-2035 (USD Billion)
  328.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  329.     7.19.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  330.     7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  331.     7.19.3 BY END USER, 2025-2035 (USD Billion)
  332.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  333.     7.20.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  334.     7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  335.     7.20.3 BY END USER, 2025-2035 (USD Billion)
  336.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  337.     7.21.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  338.     7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  339.     7.21.3 BY END USER, 2025-2035 (USD Billion)
  340.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  341.     7.22.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  342.     7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  343.     7.22.3 BY END USER, 2025-2035 (USD Billion)
  344.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  345.     7.23.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  346.     7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  347.     7.23.3 BY END USER, 2025-2035 (USD Billion)
  348.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  349.     7.24.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  350.     7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  351.     7.24.3 BY END USER, 2025-2035 (USD Billion)
  352.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  353.     7.25.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  354.     7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  355.     7.25.3 BY END USER, 2025-2035 (USD Billion)
  356.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  357.     7.26.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  358.     7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  359.     7.26.3 BY END USER, 2025-2035 (USD Billion)
  360.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  361.     7.27.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  362.     7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  363.     7.27.3 BY END USER, 2025-2035 (USD Billion)
  364.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  365.     7.28.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  366.     7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  367.     7.28.3 BY END USER, 2025-2035 (USD Billion)
  368.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  369.     7.29.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  370.     7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  371.     7.29.3 BY END USER, 2025-2035 (USD Billion)
  372.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  373.     7.30.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  374.     7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  375.     7.30.3 BY END USER, 2025-2035 (USD Billion)
  376.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  377.     7.31.1
  378.   7.32 ACQUISITION/PARTNERSHIP
  379.     7.32.1

Healthcare Market Segmentation

Healthcare By Diagnosis Method (USD Billion, 2025-2035)

  • Serological Tests
  • Molecular Tests
  • Microscopy
  • Culture Methods

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Antimonials
  • Amphotericin B
  • Miltefosine
  • Paromomycin

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions